A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
for SST2-positive Neuroendocrine Neoplasms
20 locations incl. Phoenix
Sponsor: Crinetics Pharmaceuticals Inc.
Sex: All·Age: 18+
Code: NCT07129252·Phase 1, Phase 2·Recruiting